[Recent advances in the treatment of AIDS-related malignant lymphoma].
The use of highly active antiretroviral therapy (HAART) has been associated with a reduced risk of primary cerebral and systemic non-Hodgkin's lymphoma, and improved prognosis for those who develop HIV-associated non-Hodgkin's lymphoma or Hodgkin's lymphoma. However, the number of HIV-associated non-Hodgkin's lymphoma patients has increased with the increase of HIV-1 infected patients in Japan. Although the evidence currently supports an intensive and curative approach for the management of HIV-associated lymphoma, we must be vigilant about adverse effects and interaction of chemotherapeutic drugs, implementing infection prophylaxis and promptly recognizing, diagnosing, and treating bacterial, parasitic, fungal, and viral infections that may occur as a consequence of therapy.
Division of Hematopoiesis, Center for AIDS Research, Kumamoto University.
Seiji
S
Okada
D023241:Antiretroviral Therapy, Highly Active; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*